Congrats to Yujin Seo (CMU), working with CP3’s Dr. Katie Suda, on presenting at the IQVIA Institute Research Forum. Her poster shows drug shortages hit older adults hardest, with faster fill declines among Medicare/Medicaid patients and those linked to rural or lower-income prescribers.

New study co-authored by CP3’s @timandersonmd.bsky.social shows limited lecanemab uptake in the VHA and that nearly 30% of patients had ARIA or stroke within 7 months of starting treatment, highlighting the need for careful long-term safety and effectiveness monitoring. www.mdpi.com/2077-0383/14...

Welcome to CP3! Juan M. Hincapie-Castillo (@drjuanhc.com) will join Pitt’s School of Pharmacy as Associate Professor (pending) in Jan 2026 & as a CP3 faculty affiliate. A longtime collaborator & 2024 Pharmacoequity panelist, his work focuses on legal epidemiology & evidence-based policymaking.

🆕study in @addictionjournal.bsky.social shows how lookback window & washout choices in MOUD research affect sample size, demographics, & tx start misclassification. It offers practical guidance to improve comparative studies in #opioid use disorder research. onlinelibrary.wiley.com/doi/10.1111/...

CP3 Associate Director Dr. Katie Suda was interviewed for Dr. Bicuspid on the risks of prescribing #opioids to pediatric patients. Read the interview and more on Dr. Suda's study here: www.drbicuspid.com/dental-speci...

New study finds telehealth and a gradual return to in-person visits helped restore outpatient care for patients with atrial fibrillation after the pandemic. But recovery was uneven, with notable differences by patients’ pre-pandemic outpatient use. link.springer.com/article/10.1...

🆕study finds global #drugshortages persist & disproportionately affect countries with lower GDP per capita. Essential medicines are unevenly impacted worldwide, highlighting the need for policy solutions beyond pricing to address shortages & global inequities. gh.bmj.com/content/10/1...

We had a fun watch party for our friend and colleague Dr. Lu Tang's Senior Vice Chancellor’s Research Seminar! We've been lucky to work with Dr. Tang on our risk prediction projects and enjoyed his amazing talk on innovative analytic methods for precision health care! @pittmed.bsky.social

New study led by CP3’s Dr. Jenny Lo-Ciganic presents a dynamic risk model that efficiently identifies older adults at high fall-related injury risk—offering a tool to inform clinical decisions and better target prevention resources. accpjournals.onlinelibrary.wiley.com/doi/10.1002/...

🆕 @jamahealthforum.com study of 13.8M ARB users found adherence didn’t change 18 months after the recalls, many switched to alternatives within 90 days, & switching didn’t raise insurer or out-of-pocket drug costs. jamanetwork.com/journals/jam...

Using real-world data, our colleagues (including CP3's Dr. Jenny Lo-Ciganic) found for PPH, the top-ranked risk factor was placenta previa or accreta, the top-ranked comorbidity was primary cesarean delivery, & the commonest cause was uterine atony. Read more: www.researchsquare.com/article/rs-7...

CP3's Dr. Jenny Lo-Ciganic was part of a team that examined associations between trajectories of #buprenorphine use & time to adverse outcomes among youth. Bottom line: Medication adherence may prevent overdose, ED use, and hospitalization. Read more: publications.aap.org/pediatrics/a...

CP3's @timandersonmd.bsky.social was lead author on this paper describing study results including that most hospitalized older adults discharged w/cardiometabolic 💊 changes experienced 💊 errors or gaps in discharge planning. Read more @journalgim.bsky.social: link.springer.com/article/10.1...

Growing use of antiobesity medications means that clinicians must be aware of risks and benefits of starting & stopping them. In @jamainternalmed.com, Dr. Elizabeth Oczypok & CP3's @timandersonmd.bsky.social share important lessons gleaned from research settings. jamanetwork.com/journals/jam...

The DEMONSTRATE trial will assess a #MachineLearning based clinical decision support tool to reduce #opioid harm in elevated risk patients. This paper describes the protocol that will provide real-world evidence for the tool. Read more: www.mdpi.com/2077-0383/14...

CP3's Dr. Luke Berenbrok spoke with @newsweek.com about ways #Medicare users can ensure they are using all of their benefits, especially those for OTC items. He suggests talking with community pharmacists for help with understanding what products are covered. www.newsweek.com/medicare-use...

CP3’s Dr. Julie Donohue and colleagues urge continued investment in strong, objective health policy research—calling for innovative methods and data sources to guide the future of health care and strengthen the evidence base. Read more @jamahealthforum.com: jamanetwork.com/journals/jam...

🆕 @jamainternalmed.com, CP3's @bryantshuey.bsky.social, @timandersonmd.bsky.social, & Dr. Ted Park break down new ASAM #benzodiazepine tapering guidelines, highlighting how to support safer #deprescribing, especially for high-risk patients. jamanetwork.com/journals/jam... @pittgim.bsky.social

Have you heard of Pitt's Healthy Home Lab? It's one of the innovations led by our parent org, Pitt's Health Policy Institute. In @publicsource.org, read about it and other solutions to help older adults: www.publicsource.org/pennsylvania...

ICYMI: CP3's @bryantshuey.bsky.social was recently chosen as a @nam.edu State Health Policy Fellow. Dr. Shuey will use his expertise in addiction issues to advise the PA Department of Health's Office of Drug Surveillance and Misuse Prevention. www.medschool.pitt.edu/news/bryant-...

🆕editorial co-authored by CP3’s Dr. Julie Donohue argues that as health policy enters a turbulent era, research must focus not only on access, cost, & quality, but also on system innovations, SDoH, & emerging tools like AI. @jamahealthforum.com: jamanetwork.com/journals/jam...

🆕study co-authored by CP3’s Dr. Bernie Good finds that a targeted pharmacy-care-management service ⬆️💊 adherence & ⬇️resource use among Medicare Advantage beneficiaries—supporting broader use of pharmacist-led models in managing cardiometabolic conditions. Read more: www.jmcp.org/doi/10.18553...

New study co-authored by CP3’s Dr. Katie Suda found repeat C. difficile testing within 7 days was uncommon (4.5%) but more frequent in long-term care and among resident-ordered tests—highlighting opportunities to strengthen diagnostic stewardship. www.cambridge.org/core/journal...

New study from CP3 finds buprenorphine initiation in older adults rose in 2018–19 but plateaued thru 2021 despite access efforts—showing need for targeted implementation & clinician education to boost MOUD use. @agsjournal.bsky.social agsjournals.onlinelibrary.wiley.com/doi/full/10....

New study co-authored by CP3’s Dr. Katie Suda & Yilei Liu found that 1 in 10 pediatric dental visits involving opioids led to overdose or persistent use—highest in young children. Highlights need for caution and nonopioid pain management. pubmed.ncbi.nlm.nih.gov/41081662/

New study co-authored by CP3’s Dr. Katie Suda found that antibiotic durations for common infections in older adults are often longer than guidelines recommend, highlighting opportunities to reduce overuse and improve antimicrobial stewardship. pubmed.ncbi.nlm.nih.gov/41050542/

New study co-authored by CP3’s Dr. Tom Radomski finds standard criteria for medication appropriateness may not align w/shifting goals of care in dementia. Integrating goals-of-care data could improve 💊optimization. More @agsjournal.bsky.social: agsjournals.onlinelibrary.wiley.com/doi/10.1111/...

Congratulations to our colleague @mirandayaver.bsky.social for being named one of the @academyhealth.bsky.social Champions for Health Services & Prevention Research! Well deserved! academyhealth.org/page/champio...

ICYMI, the PROTECT project, w/CP3’s @jennylociganic.bsky.social & @walidgellad.bsky.social as co-investigators, secured a NIH/NIDA grant to build an #AI clinical tool for predicting relapse in #buprenorphine patients. @pittgim.bsky.social @pittdeptofmed.bsky.social pharmacy.ufl.edu/2025/10/09/a...

🆕study co-authored by CP3’s @timandersonmd.bsky.social describes a psychologist-led mindfulness-informed CBT program designed to complement pharmacist support in helping older adults reduce or stop benzos. Next step: testing feasibility in a pilot trial. onlinelibrary.wiley.com/doi/10.1111/...

Congrats to CP3's @bryantshuey.bsky.social for being selected as a @nam.edu State Health Policy Fellow! He'll gain even more experience in advising state policymakers to improve health in PA. nam.edu/news-and-ins... @pittgim.bsky.social @pittdeptofmed.bsky.social

New preprint co-authored by CP3’s @jennylociganic.bsky.social: PGx can help match patients to safer opioids. An ensemble ML model (XGB+SVM-RBF) best predicted PGx uptake (AUC 79.6%). With further validation, it could support real-world clinical decision tools. www.medrxiv.org/content/10.1...

New study co-authored by CP3’s Dr. Ted Park finds over 1 in 5 opioid/benzo-naïve patients started 🆕Rx after surgery, while half with prior use continued. Many fills reflect preexisting use—highlighting need for tailored risk management. More @acsjacs.bsky.social: journals.lww.com/journalacs/a...

🆕study in 🫀co-authored by CP3’s @timandersonmd.bsky.social examines acute ⬆️ #bloodpressure in hospital settings. Clinicians often don’t treat it, citing uncertainty about dx thresholds & risks—highlighting need for clearer guidelines & decision support tools. More: heart.bmj.com/content/earl...

New study co-authored by CP3’s Dr. Coleman Drake finds that a 2008 federal #methadone supply restriction led patients to switch to safer formulations, preventing an estimated 1,600 #overdose deaths over two years. Read more: www.sciencedirect.com/science/arti...

We’re excited to share the launch of CP3’s new website, now hosted on the @openscholar.bsky.social platform! The site offers a fresh, unified look with other Pitt Centers and Institutes and is designed to spotlight CP3’s research projects. Take a look! cp3.pitt.edu

🆕preprint co-authored by CP3’s Dr. Julie Donohue finds ACA #Medicaid expansion in NJ & PA led to large immediate increases in Medicaid enrollment among people using homelessness assistance services, especially those with frequent service contact. www.researchsquare.com/article/rs-6...

🆕study w/ CP3 co-authors shows prescribers responded to the 2018-19 ARB (valsartan, losartan, irbesartan) recalls with large reductions in valsartan fills (↓ 57-59%), offset by increases in other ARBs. No major shift toward non-ARB antihypertensives. journals.lww.com/lww-medicalc...

🆕analysis led by CP3's Dr. Katie Suda & Tate Miner & team shows National Action Plan implementation wasn't associated with changes in antibiotic sales after 2 years. @mina-t.bsky.social @pittgim.bsky.social Read more @ichejournal.bsky.social: www.cambridge.org/core/journal...

New @journalgim.bsky.social study: VA clinicians cite evidence uncertainty, patient expectations, and system barriers as drivers of low-value care. Clearer guidance, education & aligned incentives may help reduce it. link.springer.com/article/10.1...

🆕paper, co-authored by CP3's @timandersonmd.bsky.social, describes findings that inpatient orthostatic hypotension was most often recognized after admission, but etiology and management differed across service lines. Read more: onlinelibrary.wiley.com/doi/10.1111/...

New analysis suggests restrictive state #opioid treatment program regulations limit geographic access to #methadone maintenance treatment & easing these restrictions could expand access. Read more in Health Affairs: www.healthaffairs.org/doi/10.1377/...

Though there were no differences in ED use or all-cause mortality, #Medicaid prescription cap policies were associated with increased hospitalization risk. Read more: www.sciencedirect.com/science/arti...

More than 1 in 10 opioid-naive #veterans having curative cancer surgery developed new persistent #opioid use, per a new study co-authored by CP3's Dr. Katie Suda. Optimizing pain management is key to reducing long-term opioid risks. More: acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Results suggest private equity acquisitions don't change #methadone access. Authors, incl CP3's Dr. Bryant Shuey, recommend policy makers be wary of those that "might benefit from the status quo on policies that seek to expand methadone access." More: www.healthaffairs.org/doi/10.1377/...

Not much is known about patterns of opioid prescribing & vaso-occlusive crises among individuals with sickle cell disease. CP3's Drs. Ted Park & Terri Newman & team sought to change that with this analysis. Learn what they found: www.thelancet.com/journals/lan...

CP3’s Dr. Tom Radomski received a new VA Merit grant to lead EVOLV-Rx VA, a study aimed at reducing low-value prescribing in VA Community Living Centers. The project will use an EVOLV-Rx dashboard to support pharmacists in making deprescribing recommendations. #Veterans #Deprescribing

🆕analysis from CP3's Dr. Ravy Vajravelu, @timandersonmd.bsky.social, Bridget Mayrer, & team examined the implications of recdent iron deficiency guidelines for the prevalence & management of iron deficiency anemia. Read more @jamainternalmed.com: jamanetwork.com/journals/jam...

Stimulant prescribing is ⬆️, leading to concerns about overprescribing/misuse. CP3's @timandersonmd.bsky.social & team examined post-Covid stimulant prescribing trends & noted ⬆️prescriptions by nurse practitioners & ⬆️marketing to clinicians. More @jamapediatrics.com: jamanetwork.com/journals/jam...

New paper co-authored by CP3’s #MachineLearning expert @jennylociganic.bsky.social presents a model that effectively predicts and stratifies risk of hepatitis C infection using ML algorithms—offering a powerful tool for targeted screening. Read more: academic.oup.com/ofid/article...